Abstracts tagged "axial spondyloarthritis"

Abstract Number: 1163 • 2019 ACR/ARP Annual Meeting
Erosions Are the Most Often Reported Structural Lesion on MRI of the Sacroiliac Joints in axSpA Patients with IBP
Manouk de Hooge¹, Ann-Sophie De Craemer ¹, Thomas Renson ¹, Philippe Carron ¹, Liselotte Deroo ¹, Dirk Elewaut ¹ and Filip Van den Bosch ¹, ¹Ghent University Hospital, Ghent, Belgium
Background/Purpose: HLA-B27 and sacroiliitis on MRI form the basis of the Assessment of SpondyloArthritis international Society (ASAS) axial spondyloarthritis (axSpA) classification criteria. In addition, while…
Abstract Number: 1522 • 2019 ACR/ARP Annual Meeting
Inflammatory Bowel Disease and Anterior Uveitis in Patients Treated with Ixekizumab for Radiographic Axial Spondyloarthritis: Results from Two Phase 3 Studies Through 52 Weeks
Sergio Schwartzman¹, Atul Deodhar ², Andris Kronbergs ³, Silvia Santisteban ³, Sandra Garces ³, David Sandoval ³, Jeffrey Lisse ³, Fangyi Zhao ³, Denis Poddubnyy ⁴ and James Rosenbaum ⁵, ¹The Hospital for Special Surgery, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY, ²Oregon Health & Science University, Portland, OR, ³Eli Lilly and Company, Indianapolis, IN, ⁴Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ⁵Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, Portland, OR
Background/Purpose: Radiographic axial spondyloarthritis (r-axSpA) is a chronic inflammatory disease involving the axial skeleton; inflammatory bowel disease (IBD) and acute anterior uveitis (AAU) are common…
Abstract Number: 2728 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Upadacitinib in a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2/3 Clinical Study of Patients with Active Ankylosing Spondylitis
Désirée van der Heijde¹, In-Ho Song ², Aileen Pangan ³, Atul Deodhar ⁴, Filip Van den Bosch ⁵, Walter P. Maksymowych ⁶, Tae-Hwan Kim ⁷, Mitsumasa Kishimoto ⁸, Andrea Everding ⁹, Yunxia Sui ¹⁰, Xin Wang ¹⁰, Alvina D. Chu ¹⁰ and Joachim Sieper ¹¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ³AbbVie Inc., North Chicago, ⁴Oregon Health & Science University, Portland, OR, ⁵Ghent University Hospital, Ghent, Belgium, ⁶University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ⁷Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁸Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, ⁹HRF Hamburger Rheuma Forschungszentrum, Hamburg, Germany, ¹⁰AbbVie Inc., Chicago, ¹¹Charité Universitätsmedizin Berlin, Germany, Berlin, Germany
Background/Purpose: Patients (pts) with ankylosing spondylitis (AS) who have an inadequate response/contraindication to NSAIDs have limited treatment options other than biologics. The Janus kinase (JAK)…
Abstract Number: 559 • 2019 ACR/ARP Annual Meeting
Diagnostic Utility of Individual Inflammatory Back Pain Parameters in Patients with Axial Spondyloarthritis
Manouk de Hooge¹, Floris van Gaalen ², Marleen van de Sande ³, Roberta Ramonda ⁴, Karen Fagerli ⁵, Lennart Jacobsson ⁶, Désirée van der Heijde ², Dirk Elewaut ¹ and Filip Van den Bosch ¹, ¹Ghent University Hospital, Ghent, Belgium, ²Leiden University Medical Center, Leiden, Netherlands, ³Amsterdam UMC, Amsterdam, Netherlands, ⁴University of Padova, Padova, Italy, ⁵Diakonhjemmet Hospital, Oslo, Norway, ⁶University of Göteborg, Göteborg, Sweden
Background/Purpose: A recent study in German chronic back pain (CBP) patients (pts) with a suspicion of axial spondyloarthritis (axSpA) report on the performance of, among…
Abstract Number: 595 • 2019 ACR/ARP Annual Meeting
What Is the Impact of Discrepancy Between Central and Local Readers in Evaluation of MRI Scans on the Classification of Axial Spondyloarthritis? Data from the ASAS Classification Cohort Study
Walter P. Maksymowych¹, Susanne Juhl Pedersen ², Ulrich Weber ³, Pedro Machado ⁴, Xenofon Baraliakos ⁵, Joachim Sieper ⁶, Stephanie Wichuk ⁷, Denis Poddubnyy ⁸, Martin Rudwaleit ⁹, Désirée van der Heijde ¹⁰, Robert B.M. Landewé ¹¹, Joel Paschke ¹², Mikkel Østergaard ¹³ and Robert Lambert ⁷, ¹University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Hovedstaden, Denmark, ³Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sonderborg, Denmark, ⁴University College London, London, United Kingdom, ⁵Rheumatology Department, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ⁶Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, ⁷University of Alberta, Edmonton, Canada, ⁸Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ⁹Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany, ¹⁰Leiden University Medical Center, Leiden, Netherlands, ¹¹Amsterdam University Medical Center, Amsterdam, Netherlands, ¹²CARE Arthritis, Edmonton, Canada, ¹³Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Active MRI lesions typical of axSpA were reported in 61.6% and 2.2% of axSpA and not-axSpA patients, respectively, from the ASAS classification cohort (ASAS-CC)1.…
Abstract Number: 626 • 2019 ACR/ARP Annual Meeting
Are There Really Differences Between Non-radiographic and Radiographic Axial Spondyloarthritis? Data from the Spanish Atlas
Marco Garrido-Cumbrera¹, Jordi Gratacós ², Eduardo Collantes ³, Pedro Zarco ⁴, Carlos Sastre ⁵, Sergio Sanz-Gómez ⁶ and Victoria Navarro-Compán ⁷, ¹Health & Territory Research, Universidad de Sevilla, Seville, Spain, Sevilla, ²Hospital Universitari Parc Taulí, Sabadell, I3PT, UAB, Spain, Sabadell, Spain, ³Reina Sofia University Hospital, Spain. Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba, Cordova, Spain, Cordova, Spain, ⁴Hospital Universitario Fundación Alcorcón, Madrid, Spain, Madrid, Spain, ⁵Novartis Spain, Barcelona, Spain, Barcelona, Spain, ⁶Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, Seville, Spain, ⁷University Hospital La Paz, IdiPaz, Madrid, Spain
Background/Purpose: Most research studies support the fact that both, radiographic and non-radiographic axial spondyloarthritis (r-axSpA and nr-axSpA), share similar clinical characteristics and equivalent burden of…
Abstract Number: 1175 • 2019 ACR/ARP Annual Meeting
Periarticular Inflammation and Bone Marrow Oedema Are Important in the Evaluation of Enthesitis on MRI in Patients with Peripheral and Axial SpA
Xenofon Baraliakos¹, Philipp Sewerin ², Eugenio de Miguel ³, Christine Kleinmond ⁴, Ankita Shekhawat ⁵, Annette Wiedon ⁶ and Frank Behrens ⁷, ¹Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ²Department of Rheumatology & Hiller Research Unit, University Hospital Düsseldorf,, Duesseldorf, Germany, ³Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ⁴ClinProject GmbH, Eurasburg, Germany, ⁵Novartis Healthcare Pvt. Ltd., Hyderabad, India, ⁶Novartis Pharma GmbH, Nürnberg, Germany, ⁷CIRI/Rheumatology and Fraunhofer TMP, Goethe-University, Frankfurt, Germany
Background/Purpose: Enthesitis is a hallmark feature of Spondyloarthritis (SpA), and frequently localizes at the Achilles tendon1. Enthesitis is predominantly measured with clinical scores like Leeds…
Abstract Number: 1540 • 2019 ACR/ARP Annual Meeting
Biologic Use and Reasons for Switching Biologic Therapy in Patients with Non-radiographic Axial Spondyloarthritis in the United States:Findings from a US Survey
Atul Deodhar ¹, Theresa Hunter², Elizabeth Holdsworth ³, Nicola Booth ⁴ and David Sandoval ⁵, ¹Oregon Health & Science University, Portland, OR, ²Eli Lilly and Company, Indianapolis, ³Adelphi Real World, Manchester, England, United Kingdom, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Eli Lilly and Company, Indianapolis, IN
Background/Purpose: The FDA approved the first biologic for the treatment of nr-axSpA in the US in March 2019. The objective of our study was to…
Abstract Number: 2754 • 2019 ACR/ARP Annual Meeting
AxSpA Patients with Symptom Onset < 30 Years Have More Structural Lesions on MRI of the Sacroiliac Joints When Fulfilling the Modified New York Criteria
Manouk de Hooge¹, Ann-Sophie De Craemer ¹, Thomas Renson ¹, Philippe Carron ¹, Liselotte Deroo ¹, Dirk Elewaut ¹ and Filip Van den Bosch ¹, ¹Ghent University Hospital, Ghent, Belgium
Background/Purpose: The modified New York criteria (mNY) combine clinical symptoms with radiographic sacroiliitis on conventional pelvic radiographs (X-SI) classifying radiographic axial SpA patients (r-axSpA). AxSpA…
Abstract Number: 561 • 2019 ACR/ARP Annual Meeting
Analysing Impairments in Physical Performance as Assessed by the as Performance Index (ASPI) in Patients with Axial Spondyloarthritis (axSpA)
Eerik Ahomaa ¹, Uta Kiltz², Björn Bühring ³, Xenofon Baraliakos ⁴, Salima van weely ⁵ and Jürgen Braun ⁶, ¹Rheumazentrum Ruhrgebiet and Ruhr-University Bochum, Bochum, Germany, ²Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ³Rheumazentrum Ruhrgebiet and Ruhr-University Bochum, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁵Orthopedics, Rehabilitation and Physical Therapy dpt., Leiden University Medical Center, Leiden, Netherlands, ⁶Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany
Background/Purpose: In patients with axial spondyloarthritis (axSpA) physical functioning is frequently impaired. The current gold standard to assess physical functioning is self-reported questionnaires (i.e. BASFI),…
Abstract Number: 600 • 2019 ACR/ARP Annual Meeting
Frequency of Disease Flares Under Long-Term Anti-TNF Therapy in Patients with Early Axial Spondyloarthritis: Results from the Etanercept versus Sulfasalazine in Early Axial Spondyloarthritis Trial (ESTHER)
Fabian Proft¹, Murat Torgutalp ², Anja Weiß ³, Mikhail Protopopov ⁴, Valeria Rios Rodriguez ⁵, Hildrun Haibel ¹, Kay-Geert Hermann ⁵, Christian Althoff ⁵, Olaf Behmer ⁶, Joachim Sieper ¹ and Denis Poddubnyy ⁷, ¹Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Germany and Ankara University Faculty of Medicine, Ankara, Turkey., Berlin, Germany, ³German Rheumatism Research Center (DRFZ), Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Germany, Berlin, Berlin, Germany, ⁵Charité Universitätsmedizin, Berlin, Germany, ⁶Pfizer Inc., Berlin, Germany, ⁷Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany
Background/Purpose: Disease flares in axial spondyloarthritis (axSpA) might occur even in patients with otherwise stable disease receiving effective anti-inflammatory therapy such as TNF inhibitors. The…
Abstract Number: 630 • 2019 ACR/ARP Annual Meeting
Assessing the Humanistic and Economic Burden of Enthesitis Among Patients with Peripheral and Axial Spondyloarthritis: Results from a Multi-National Real World Survey Database
Vibeke Strand ¹, Atul Deodhar ², Philip G Conaghan ³, Isabelle Gilloteau ⁴, Olivia Massey ⁵, Haijun Tian ⁶, Aurore Yocolly ⁷, Nicola Booth⁵ and Rieke Alten ⁸, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²Oregon Health & Science University, Portland, OR, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Adelphi Real World, Bollington, United Kingdom, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Novartis Product Lifecycle Services –NBS, Novartis Global Service Center, Dublin, Ireland, ⁸Schlosspark-Klinik University Medicine, Berlin, Germany
Background/Purpose: Enthesitis is a major source of pain, functional impairment, and reduced health-related quality of life (HRQoL) in spondyloarthritis (SpA) patients; however, limited information is…
Abstract Number: 1431 • 2019 ACR/ARP Annual Meeting
Real-Life Golimumab Persistence in Patients with Chronic Inflammatory Rheumatic Disease: Results of the GO PRACTICE Study
René-Marc Flipo¹, Florence Tubach ², Jean Ouaniche ³, Philippe Goupille ⁴, Eric Lespessailles ⁵, Najat Gouyette ⁶, Naoual Harid ⁷, Saannya Sequiera ⁸, Philippe Bertin ⁹ and Bruno Fautrel ¹⁰, ¹Roger Salengro University-Hospital, Lille , France, Lille, France, ²Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France, ³Private Practice , Toulon, France, Toulon, France, ⁴Tours University-Hospital, Tours, France, Tours, France, ⁵Orléans Regional Hospitals, Orléans ,France, Orléans, France, ⁶MSD France, Courbevoie ,France, Courbevoie, Ile-de-France, France, ⁷MSD France, Courbevoie, France, Courbevoie, Ile-de-France, France, ⁸ClinSearch ,Malakoff, France, Malakoff, Ile-de-France, France, ⁹Limoges University-Hospital , Limoges, France, Limoges, France, ¹⁰Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France
Background/Purpose: The GO PRACTICE study was initiated following a demand by the French Health Authorities for long-term data on the real-life use of golimumab (GLM)…
Abstract Number: 1544 • 2019 ACR/ARP Annual Meeting
Predictors of Response, Adverse Events and Treatment Retention in Ankylosing Spondylitis Patients Treated with Golimumab in a Prospective, Observational Registry
Proton Rahman ¹, Ariel Masetto ², Michelle Teo ³, Pauline Boulos ⁴, Dalton Sholter ⁵, Suneil Kapur ⁶, Emmanouil Rampakakis ⁷, Meagan Rachich ⁸, Odalis Asin-Milan ⁸, Allen Lehman ⁸ and Francois Nantel⁸, ¹Memorial University, Newfoundland, NL, Canada, ²Université de Sherbrooke, Sherbrooke, QC, Canada, ³Balfour Medical Clinic, Penticton, BC, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵Rheumatology Associates, Edmonton, AB, Canada, ⁶University of Ottawa, Ottawa, ON, Canada, ⁷JSS Medical Research, Montreal, Canada, ⁸Janssen Inc., Toronto, ON, Canada
Background/Purpose: The Biologic Treatment Registry Across Canada (BioTRAC) was a prospective, observational registry that enrolled ankylosing spondylitis (AS) (radiographic axial SpA) patients treated with subcutaneous…
Abstract Number: 2774 • 2019 ACR/ARP Annual Meeting
Cluster-based Spondyloarthritis Phenotypes Defined at Baseline Are Predictive of Different Severity Outcomes at 5-Year in the DESIR Cohort
Félicie Costantino ¹, Philippe Aegerter ², Anna Moltó ³, Georg Schett ⁴, Maxime Breban ⁵ and Maria-Antonietta D'Agostino⁶, ¹UMR1173, INSERM/Versailles-Saint Quentin University, France Ambroise Paré Hospital (AP-HP) Department of Rheumatology, Boulogne-Billancourt, France, Boulogne Billancourt, France, ²Public Health Department - GIRCI IdF - INSERM/Versailles-Saint Quentin University, France, Versailles, France, ³Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, ⁴Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, ⁵UMR1173, INSERM/Versailles-Saint Quentin University, France Ambroise Paré Hospital (AP-HP) Department of Rheumatology, Boulogne-Billancourt, France, Boulogne Billancourt, ⁶UMR1173, INSERM/Versailles-Saint Quentin University, France Ambroise Paré Hospital (AP-HP) Department of Rheumatology, Boulogne Billancourt, France
Background/Purpose: The course of axial spondyloarthritis (SpA) is heterogeneous and remains to be better defined. DESIR is a longitudinal French cohort of early undifferentiated axial…

« Previous Page
1
…
4
5
6
7
8
…
16
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].